Results 11 to 20 of about 22,433 (204)
Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements. [PDF]
Milbank QPolicy Points States contract with Medicaid managed care plans to administer benefits for roughly 70 million Medicaid enrollees, yet little is known about how plan benefit policies for substance use disorder (SUD) treatment medications align with state requirements.
Feltus SR +6 more
europepmc +2 more sources
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives In rare diseases like progressive familial intrahepatic cholestasis (PFIC), lack of evidence results in treatment variability and strategies for families to engage care teams to understand how variability affects overall health are unknown.
James E. Squires +7 more
wiley +1 more source
Hell's Itch: A Self‐Case Report
JEADV Clinical Practice, EarlyView.ABSTRACT Hell's itch is a severely distressing dermatological condition characterized by the onset of incessant itching and intolerable pain 2–3 days post‐sunburn. It is underdiagnosed and underreported, and no definitive management framework has yet been developed.
Kai Peter Moors, Willem I. Visser
wiley +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley +1 more source
Prevalence of Pre‐Clinical Obesity Among US Adults Receiving Medical and Surgical Obesity Treatment
Obesity, EarlyView.ABSTRACT Objective We sought to determine how the proportion of adults historically receiving obesity interventions would be classified under the recently proposed “pre‐clinical” and “clinical” obesity classifications and the impact of this change on safety and outcomes.
Jason M. Samuels +4 more
wiley +1 more source
Effects of cannabidiol plus naltrexone on motivation and ethanol consumption
, 2018 [Background and Purpose] The aim of this study was to explore if the administration of naltrexone together with cannabidiol (CBD) may improve the efficacy in reducing alcohol consumption and motivation rather than any of the drugs given separately ...
García-Gutiérrez, María Salud +12 more
core +1 more source
, 2021 Purpose: The precise mechanisms that naltrexone acts on the brain to improve alcohol dependence treatment outcomes is unknown. Naltrexone is a Mu- opioid antagonist that blocks endogenous opioid reward and is thought to reduce alcohol cue-conditioned ...
Connor, JP +7 more
core +1 more source
Obesity, EarlyView.ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu +5 more
wiley +1 more source
Asymmetric synthesis of (−)-naltrexone
Chemical Science, 2019 The asymmetric synthesis of (−)-naltrexone was achieved by a Rh(i)-catalyzed C–H alkenylation and torquoselective electrocyclization cascade and late-stage C–H hydroxylation.
Sun Dongbang +2 more
openaire +3 more sources